BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 12389335)

  • 1. Insulin-like growth factor I polymorphism and breast cancer risk in Jewish women.
    Figer A; Karasik YP; Baruch RG; Chetrit A; Papa MZ; Sade RB; Rizel S; Friedman E
    Isr Med Assoc J; 2002 Oct; 4(10):759-62. PubMed ID: 12389335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic variation in IGF-1 and breast cancer risk in Ashkenazi carriers and noncarriers of BRCA1/2 mutations.
    Khoury-Shakour S; Lejbkowicz F; Barnett-Griness O; Tamir A; Pinchev M; Rennert G
    Eur J Cancer Prev; 2009 Sep; 18(5):361-7. PubMed ID: 19543094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRCA1 breast cancer risk is modified by CYP19 polymorphisms in Ashkenazi Jews.
    Raskin L; Lejbkowicz F; Barnett-Griness O; Dishon S; Almog R; Rennert G
    Cancer Epidemiol Biomarkers Prev; 2009 May; 18(5):1617-23. PubMed ID: 19366906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coinheritance of BRCA1 and BRCA2 mutations with Fanconi anemia and Bloom syndrome mutations in Ashkenazi Jewish population: possible role in risk modification for cancer development.
    Koren-Michowitz M; Friedman E; Gershoni-Baruch R; Brok-Simoni F; Patael Y; Rechavi G; Amariglio N
    Am J Hematol; 2005 Mar; 78(3):203-6. PubMed ID: 15726604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-nucleotide polymorphisms in the p53 pathway genes modify cancer risk in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent.
    Yarden RI; Friedman E; Metsuyanim S; Olender T; Ben-Asher E; Papa MZ
    Mol Carcinog; 2010 Jun; 49(6):545-55. PubMed ID: 20306497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen receptor CAG repeat length in Jewish Israeli women who are BRCA1/2 mutation carriers: association with breast/ovarian cancer phenotype.
    Dagan E; Friedman E; Paperna T; Carmi N; Gershoni-Baruch R
    Eur J Hum Genet; 2002 Nov; 10(11):724-8. PubMed ID: 12404104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High incidence of BRCA1-2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma.
    Biron-Shental T; Drucker L; Altaras M; Bernheim J; Fishman A
    Eur J Surg Oncol; 2006 Dec; 32(10):1097-100. PubMed ID: 16650962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormone replacement therapy is more prevalent among Jewish BRCA1/2 mutation carriers.
    Sade RB; Chetrit A; Figer A; Papa MZ; Flex D; Rizel S; Friedman E
    Eur J Cancer; 2006 Mar; 42(5):650-5. PubMed ID: 16464572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population.
    Simchoni S; Friedman E; Kaufman B; Gershoni-Baruch R; Orr-Urtreger A; Kedar-Barnes I; Shiri-Sverdlov R; Dagan E; Tsabari S; Shohat M; Catane R; King MC; Lahad A; Levy-Lahad E
    Proc Natl Acad Sci U S A; 2006 Mar; 103(10):3770-4. PubMed ID: 16537453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
    Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A specific RAD51 haplotype increases breast cancer risk in Jewish non-Ashkenazi high-risk women.
    Gal I; Kimmel G; Gershoni-Baruch R; Papa MZ; Dagan E; Shamir R; Friedman E
    Eur J Cancer; 2006 May; 42(8):1129-34. PubMed ID: 16624550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRCA germline mutations in Jewish women with uterine serous papillary carcinoma.
    Lavie O; Hornreich G; Ben-Arie A; Rennert G; Cohen Y; Keidar R; Sagi S; Lahad EL; Auslander R; Beller U
    Gynecol Oncol; 2004 Feb; 92(2):521-4. PubMed ID: 14766242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype-phenotype correlations.
    Gallardo M; Silva A; Rubio L; Alvarez C; Torrealba C; Salinas M; Tapia T; Faundez P; Palma L; Riccio ME; Paredes H; Rodriguez M; Cruz A; Rousseau C; King MC; Camus M; Alvarez M; Carvallo P
    Breast Cancer Res Treat; 2006 Jan; 95(1):81-7. PubMed ID: 16261400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Segregation analysis of 231 Ashkenazi Jewish families for evidence of additional breast cancer susceptibility genes.
    Kaufman DJ; Beaty TH; Struewing JP
    Cancer Epidemiol Biomarkers Prev; 2003 Oct; 12(10):1045-52. PubMed ID: 14578141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Common BRCA2 variants and modification of breast and ovarian cancer risk in BRCA1 mutation carriers.
    Hughes DJ; Ginolhac SM; Coupier I; Corbex M; Bressac-de-Paillerets B; Chompret A; Bignon YJ; Uhrhammer N; Lasset C; Giraud S; Hardouin A; Berthet P; Peyrat JP; Fournier J; Nogues C; Lidereau R; Muller D; Fricker JP; Longy M; Toulas C; Guimbaud R; Maugard C; Olschwang S; Yannoukakos D; Durocher F; Moisan AM; Simard J; Mazoyer S; Lynch HT; Szabo C; Lenoir GM; Goldgar DE; Stoppa-Lyonnet D; Sinilnikova OM
    Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):265-7. PubMed ID: 15668505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRCA1 and BRCA2 germline mutations in Korean patients with sporadic breast cancer.
    Seo JH; Cho DY; Ahn SH; Yoon KS; Kang CS; Cho HM; Lee HS; Choe JJ; Choi CW; Kim BS; Shin SW; Kim YH; Kim JS; Son GS; Lee JB; Koo BH
    Hum Mutat; 2004 Oct; 24(4):350. PubMed ID: 15365993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
    J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The AIB1 glutamine repeat polymorphism is not associated with risk of breast cancer before age 40 years in Australian women.
    Montgomery KG; Chang JH; Gertig DM; Dite GS; McCredie MR; Giles GG; Southey MC; Hopper JL; Campbell IG
    Breast Cancer Res; 2005; 7(3):R353-6. PubMed ID: 15987430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.
    Walker LC; Waddell N; Ten Haaf A; ; Grimmond S; Spurdle AB
    Breast Cancer Res Treat; 2008 Nov; 112(2):229-36. PubMed ID: 18095154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of germline BRCA1 and BRCA2 genetic alterations in Greek breast cancer moderate-risk and low-risk individuals--correlation with clinicopathological data.
    Kataki A; Gomatos I; Pararas N; Armakolas A; Panousopoulos D; Karantzikos G; Voros D; Zografos G; Markopoulos C; Leandros E; Konstadoulakis M
    Clin Genet; 2005 Apr; 67(4):322-9. PubMed ID: 15733268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.